There is no FDA-approved CJC-1295 ipamorelin dosage for anti-aging, muscle gain, recovery, or weight loss. Human studies tested CJC-1295 and ipamorelin mostly as separate drugs, not as a combined wellness protocol. Online charts are clinic or community conventions, so dosing questions belong with a licensed clinician.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the short answer on CJC-1295 ipamorelin dosage?
CJC-1295/ipamorelin does not have a validated standard dose, because the combination has not been proven as a single FDA-approved regimen. Human studies show that each peptide can affect growth hormone biology, but separate-agent studies do not establish a combined anti-aging or body-composition protocol 1 2.
Why there is no validated combined dose
CJC-1295 and ipamorelin act on different receptors in the growth hormone system. CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, while ipamorelin acts at the ghrelin receptor, also called GHS-R1a 1 2.
That mechanism is why people combine them in wellness and performance settings. But mechanism is not the same as a clinical protocol. A dose becomes validated only after studies test the exact ingredient, form, route, schedule, outcomes, side effects, and population.
What are CJC-1295 and ipamorelin?
CJC-1295 is a synthetic growth hormone-releasing hormone analog, and ipamorelin is a growth hormone secretagogue also known in research as NNC 26-0161. Both are discussed as peptides that may raise growth hormone signals, but neither is FDA-approved for anti-aging, fat loss, muscle gain, or recovery.
CJC-1295: a long-acting growth hormone-releasing hormone analog
CJC-1295 was designed to last longer than natural GHRH. In a healthy-adult trial, it increased growth hormone and insulin-like growth factor 1, or IGF-1, for days after subcutaneous injection 1.
Another clinical study found that growth hormone secretion stayed pulsatile during continuous stimulation by CJC-1295, meaning the body still released growth hormone in pulses rather than as a flat signal 4. That finding is biologically interesting, but it does not prove benefits for sleep, recovery, body composition, or longevity.
Ipamorelin: a ghrelin-receptor growth hormone secretagogue
Ipamorelin binds the ghrelin receptor, GHS-R1a, and can stimulate growth hormone release in human volunteer pharmacology studies 2. It has also been studied in a very different medical context: postoperative ileus after bowel resection, where researchers tested whether a ghrelin mimetic could help bowel function return 3.
Why people combine them in wellness and performance settings
People combine them because one peptide mimics a GHRH signal and the other mimics a ghrelin-receptor signal. In theory, that could create a stronger growth hormone pulse than either pathway alone, but published human trials of the exact combined CJC-1295/ipamorelin wellness stack are lacking.
If you are comparing this pair with other growth-hormone peptides, our guide to CJC-1295/ipamorelin vs sermorelin explains why the evidence and access questions differ.
What doses were actually studied in humans?
Human dosing data exist for CJC-1295 and ipamorelin as separate agents, but these are research doses, not instructions for readers. The key point is that studied doses were tied to specific protocols, populations, and monitoring plans.
| Agent or study | What was studied | Dose detail from the source | What it can and cannot tell you |
|---|---|---|---|
| CJC-1295 in healthy adults | Long-acting GHRH analog given by subcutaneous injection | Single ascending doses from 30 to 250 μg/kg were studied in healthy adults 1. | Shows hormone-response pharmacology. It does not create a home dosing protocol. |
| CJC-1295 continuous-stimulation study | Whether GH pulsatility persisted during CJC-1295 exposure | A clinical trial evaluated pulsatile GH secretion during continuous stimulation by CJC-1295 4. | Supports mechanism. It does not prove anti-aging or body-composition benefit. |
| Ipamorelin in human volunteers | Pharmacokinetic and pharmacodynamic modeling of a GH-releasing peptide | Human volunteer dose-response pharmacology was modeled for ipamorelin 2. | Shows GH-release biology. It does not validate a CJC-1295/ipamorelin blend dose. |
| Ipamorelin in bowel surgery patients | Ghrelin mimetic studied for postoperative ileus after bowel resection | A randomized proof-of-concept trial studied ipamorelin in postoperative ileus 3. | This is not an anti-aging, muscle, or fat-loss study. |
| CJC-1295 in HIV visceral obesity | Registered Phase 2 study in HIV patients with visceral obesity | ClinicalTrials.gov lists the study as terminated with planned enrollment of 120 7. | A terminated registry entry should not be used to claim proven body-composition benefit. |
Why separate-agent trials do not prove a combined protocol
A combined vial changes the question. The dose ratio, total peptide amount, route, timing, and monitoring plan all matter. A CJC-1295 trial plus an ipamorelin trial does not equal proof that a mixed vial is safe or effective for a wellness goal.
Why do online CJC-1295 ipamorelin dosing charts disagree?
Online dosing charts disagree because they often describe different ingredients while using similar names. The biggest problems are DAC vs no-DAC confusion, blend-vial math, and research-use conventions being copied as if they were prescriptions.
- DAC vs no-DAC confusion: CJC-1295 with DAC is longer acting. “CJC-1295 no DAC” is often used online to mean Modified GRF 1-29, a shorter-acting GHRH analog. These are not the same discussion.
- Blend-vial units vs micrograms: Insulin-syringe units are volume marks, not a dose by themselves. Units only make sense if you know the vial amount, peptide ratio, and reconstitution volume.
- Research-use conventions vs prescription care: Online protocols often come from community or clinic habits, not FDA-approved labeling or randomized combination trials.
- Reconstitution math risk: Bacteriostatic water volume changes concentration. A chart made for one vial can be wrong for another vial.
This is why online calculators can be misleading. We explain the math limits in more detail in our guide to CJC-1295 and ipamorelin dosage calculators.
What is the difference between CJC-1295 with DAC and CJC-1295 no DAC?
CJC-1295 with DAC is designed for longer exposure, while “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a shorter-acting GHRH analog. That difference changes how people talk about timing, frequency, and monitoring.
CJC-1295 with DAC and longer GH/IGF-1 stimulation
DAC means drug affinity complex. It helps CJC-1295 bind albumin, which can extend exposure and was part of why healthy-adult studies found multi-day growth hormone and IGF-1 effects after subcutaneous dosing 1.
Modified GRF 1-29 as the common no-DAC reference
Modified GRF 1-29 is shorter acting and is often called CJC-1295 no DAC online. That naming can cause real confusion because a person may think they are comparing two schedules for one drug, when they may be looking at different peptides.
If you want a deeper plain-English explanation, read our article on CJC-1295 no DAC and Modified GRF 1-29.
What safety issues should patients know before considering CJC-1295 or ipamorelin?
Growth-hormone peptides can affect more than one body system, so benefits should never be discussed without risks. Human studies monitored hormone effects and adverse events, but the long-term safety of combined wellness use is not established 1 2.
Side effects reported or monitored in human studies
Human CJC-1295 research focused on growth hormone and IGF-1 response, with safety monitoring in healthy adults 1. Possible concerns with growth-hormone pathway stimulation include swelling, joint or muscle discomfort, numbness or tingling, headache, glucose changes, and changes in IGF-1, though the exact risk depends on the compound, dose, route, and person.
Ipamorelin has been studied in human volunteers and in postoperative patients, but that does not answer long-term use questions in healthy people seeking body-composition or anti-aging effects 2 3. For a broader safety overview, see our guide to peptide side effects.
FDA concerns and compounding-status issues
For compounded drugs, FDA bulk-substance policy matters. FDA explains that 503A bulk drug substances must meet legal and policy requirements, and the regulation at 21 CFR Part 216 addresses substances that may not be used in compounding 8 9.
Athlete considerations and prohibited-list risk
Synthetic GHRH analogs are relevant to drug testing, and researchers have worked on detection methods for these compounds 6. The World Anti-Doping Agency prohibits growth hormone and related releasing factors in sport, so tested athletes should verify rules before using any growth-hormone secretagogue 10.
Who should not self-experiment without medical evaluation
People with a history of cancer, pituitary disease, uncontrolled diabetes risk, severe sleep apnea, unexplained swelling, active serious illness, pregnancy, or breastfeeding should not self-experiment with growth-hormone peptides. These situations need clinician review because growth hormone and IGF-1 signaling can intersect with glucose control, fluid balance, and cell-growth pathways.
How should patients think about cycles, timing, and monitoring?
Cycle length and timing claims for CJC-1295/ipamorelin are not validated clinical standards. Bedtime, fasting, five-days-on schedules, and multi-dose routines are usually protocol conventions, not FDA-approved instructions.
A licensed clinician may consider baseline symptoms, medication list, medical history, glucose markers, IGF-1, and other labs before discussing any growth-hormone pathway drug. Monitoring matters because hormone changes can create side effects even when a peptide is marketed as “natural” or “supportive.”
Stop self-directed use and contact a clinician urgently for severe headache, vision changes, chest pain, shortness of breath, severe swelling, allergic symptoms, infection signs at an injection site, or new neurologic symptoms. These are safety signals, not normal adjustment effects.
What can Chia help with if it does not offer CJC-1295 or ipamorelin?
Chia does not offer CJC-1295 or ipamorelin. We can help patients talk through goals, risks, and legitimate access questions, and when clinically appropriate our providers may consider sermorelin, a different growth hormone-releasing hormone analog available through Chia.
At Chia, treatment starts 100% online with a short health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate. A prescription is never guaranteed, and some patients are directed toward education, lab follow-up, or another type of care instead.
| Option | Does Chia offer it? | Forms listed in Chia’s catalog | How to think about it |
|---|---|---|---|
| CJC-1295 | No | Not offered | Education only; no Chia prescription path. |
| Ipamorelin | No | Not offered | Education only; no Chia prescription path. |
| Sermorelin | Yes | Injection, nasal spray, tablets | Provider-reviewed option when clinically appropriate; plans currently start at $179/mo on the sermorelin page. |
Sermorelin is not the same as CJC-1295/ipamorelin. It has its own evidence, risks, and monitoring questions. For a fuller comparison, see our guides to sermorelin peptide therapy and CJC-1295/ipamorelin vs sermorelin.
3-min quiz
Talk through peptide options with a licensed provider
Chia does not offer CJC-1295 or ipamorelin. If you want to discuss whether sermorelin or education-only guidance fits your goals, you can start online. A licensed provider reviews your health history and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved.
What questions should you ask a licensed provider before using any growth-hormone peptide?
A good peptide visit should answer ingredient, legal, pharmacy, safety, and follow-up questions before any prescription is considered. The safer path is a licensed provider plus a state-licensed 503A pharmacy, not a no-prescription research seller.
- 1Is this peptide FDA-approved for my goal, or is this off-label or investigational use?
- 2What is the exact ingredient: CJC-1295 with DAC, Modified GRF 1-29, ipamorelin, sermorelin, or a blend?
- 3What is the route and form: subcutaneous injection, nasal spray, tablet, or cream?
- 4What pharmacy is compounding it, and is it a state-licensed 503A pharmacy or a 503B outsourcing facility?
- 5How will dosing be chosen, and what labs or symptoms will be monitored?
- 6What side effects should make me stop and contact the care team?
- 7If I compete in sport, is this allowed under the WADA prohibited list or my league rules?
If a seller cannot answer basic ingredient, concentration, pharmacy, and monitoring questions, that is a reason to pause. Our guide on finding a legitimate peptide source explains how to think about licensed access versus research-only vendors.
3-min quiz
Start with a clinician-reviewed path
If your goal is to understand peptide options rather than copy an online chart, Chia can help you start with a licensed-provider review. Chia does not prescribe CJC-1295 or ipamorelin, but we do offer sermorelin when clinically appropriate through US 503A pharmacy partners with home delivery. A prescription requires medical evaluation and is never guaranteed.
FAQ
There is no standard FDA-approved CJC-1295/ipamorelin dosage for anti-aging, aesthetics, recovery, muscle gain, or weight loss. Human studies tested the ingredients mainly as separate agents, so online combined-dose charts should not be treated as medical instructions.
No. CJC-1295 with DAC is a longer-acting form designed to extend exposure. “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a shorter-acting GHRH analog. The name difference matters for timing, monitoring, and safety discussions.
Not safely from units alone. Syringe units measure volume, not peptide amount. You would need the exact vial content, peptide ratio, concentration, and reconstitution volume. A chart made for one vial can be wrong for another.
Ipamorelin is not FDA-approved for anti-aging, fat loss, muscle gain, recovery, or general wellness. It has been studied in human pharmacology and postoperative research settings, but that does not make it an approved consumer treatment.
Compounding status depends on FDA bulk-substance policy, federal law, and state pharmacy rules. CJC-1295 and ipamorelin are not treatments Chia offers. Patients should check current FDA information and avoid no-prescription research chemical sellers.
No. Chia does not offer CJC-1295 or ipamorelin. Chia does offer sermorelin in injection, nasal spray, and tablet forms when a licensed provider decides it is clinically appropriate after an online evaluation.
A safer next step is not to copy a dosing chart. It is to review your goals, medical history, medications, labs, and sport rules with a licensed clinician. For some patients, sermorelin may be discussed; for others, education or non-peptide care may be the right path.
References
- 1.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 2.Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999.
- 3.Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014.
- 4.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 5.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 6.Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021.
- 7.ClinicalTrials.gov. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. NCT00267527. 2026.
- 8.U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. 2026.
- 9.Electronic Code of Federal Regulations. Title 21, Chapter I, Subchapter D, Part 216: Human Drugs; Drug Products Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. 2026.
- 10.World Anti-Doping Agency. The Prohibited List. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
